EXACT SCIENCES CORP 4

EVP Brian Baranick had 33,321 shares awarded and all 137,195 common shares (plus 795 401(k) shares and 28,063 RSUs) cashed out or converted in Abbott’s merger with Exact Sciences at $105.00 per share, leaving him with no remaining Exact Sciences stock.

On March 23, 2026, in connection with Abbott Laboratories’ acquisition of Exact Sciences Corporation, EVP and GM of Precision Oncology Brian Baranick received an award of 33,321 shares of Exact Sciences common stock, likely reflecting settlement or conversion of equity awards at the $105.00 per share merger consideration, bringing his direct holdings to 137,195 shares before they were simultaneously cancelled for cash in the merger. At the effective time, all of his 137,195 directly held common shares were converted into the right to receive $105.00 per share in cash, his 795 shares held in a 401(k) plan were likewise converted for cash, and 28,063 restricted stock units were cancelled and converted into the right to receive cash based on the same merger consideration, with certain RSUs granted on or after November 19, 2025 being assumed by Abbott as replacement RSUs on substantially similar terms. Following these merger-related transactions, Baranick reported no continuing ownership of Exact Sciences common stock, as the issuer became a wholly owned subsidiary of Abbott Laboratories.

Filing Facts

CIK

1124140

Ticker

EXAS

Form

4

Source Type

sec

Accession

0001193125-26-118765

Alert Tier

7